Recombinant bactericidal/permeability-increasing protein rBPI21 protects against pneumococcal disease

Infection and Immunity

Volumn 75, Issue 1, 2007, Pages 342-349

  Srivastava, Amit ^a   Casey, Heather ^a   Johnson, Nathaniel ^a   Levy, Ofer ^a   Malley, Richard ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOLYSIN; RECOMBINANT BACTERICIDAL PERMEABILITY INCREASING PROTEIN; RECOMBINANT BACTERICIDAL PERMEABILITY INCREASING PROTEIN 21; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BACTERIAL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; SUPERNATANT;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; APOPTOSIS; BACTERIAL PROTEINS; BLOOD PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; HUMANS; MACROPHAGES; MEMBRANE PROTEINS; MICE; PEPTIDES; PNEUMOCOCCAL INFECTIONS; RECOMBINANT PROTEINS; STREPTOCOCCUS PNEUMONIAE; STREPTOLYSINS; TOLL-LIKE RECEPTOR 4;

EID: 33846023373     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.01089-06     Document Type: Article

References (47)

1. Akashi, S., S. Saitoh, Y. Wakabayashi, T. Kikuchi, N. Takamura, Y. Nagai, Y. Kusumoto, K. Fukase, S. Kusumoto, Y. Adachi, A. Kosugi, and K. Miyake. 2003. Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14. J. Exp. Med. 198: 1035-1042.
2. Akira, S., and K. Takeda. 2004. Toll-like receptor signalling. Nat. Rev. Immunol. 4:499-511.
3. Beamer, L. J. 2003. Structure of human BPI (bactericidal/ permeability-increasing protein) and implications for related proteins. Biochem. Soc. Trans. 31:791-794.
4. Beamer, L. J., S. F. Carroll, and D. Eisenberg. 1997. Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. Science 276:1861-1864.
5. Bergstrom, C. T., M. Lipsitch, and B. R. Levin. 2000. Natural selection, infectious transfer and the existence conditions for bacterial plasmids. Genetics 155:1505-1519.
6. Branger, J., S. Knapp, S. Weijer, J. C. Leemans, J. M. Pater, P. Specimen, S. Florquin, and T. van der Poll. 2004. Role of Toll-like receptor 4 in gram-positive and gram-negative pneumonia in mice. Infect. Immun. 72: 788-794.
7. Brown, J. S., T. Hussell, S. M. Gilliland, D. W. Holden, J. C. Paton, M. R. Ehrenstein, M. J. Walport, and M. Botto. 2002. The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc. Natl. Acad. Sci. USA 99:16969-16974.
8. Canny, G., E. Cario, A. Lennartsson, U. Gullberg, C. Brennan, O. Levy, and S. P. Colgan. 2006. Functional and biochemical characterization of epithelial bactericidal/permeability-increasing protein. Am. J. Physiol. Gastrointest. Liver Physiol. 290:G557-G567.
9. 2-terminal fragment with isolated LPS and intact Proteus mirabilis and Escherichia coli. Infect. Immun. 62:259-265.
10. Cundell, D. R., N. P. Gerard, C. Gerard, I. Idanpaan-Heikkila, and E. I. Tuomanen. 1995. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature 377:435-438.
11. Echchannaoui, H., K. Frei, C. Schnell, S. L. Leib, W. Zimmerli, and R. Landmann. 2002. Toll-like receptor 2-deficient mice are highly susceptible to Streptococcus pneumoniae meningitis because of reduced bacterial clearing and enhanced inflammation. J. Infect. Dis. 186:798-806.
12. Eckert, M., I. Wittmann, M. Rollinghoff, A. Gessner, and M. Schnare. 2006. Endotoxin-induced expression of murine bactericidal permeability/increasing protein is mediated exclusively by toll/IL-1 receptor domain-containing adaptor inducing IFN-beta-dependent pathways. J. Immunol. 176:522-528.
13. Gould, J. M., and J. N. Weiser. 2001. Expression of C-reactive protein in the human respiratory tract. Infect. Immun. 69:1747-1754.
14. Han, S. H., J. H. Kim, M. Martin, S. M. Michalek, and M. H. Nahm. 2003. Pneumococcal lipoteichoic acid (LTA) is not as potent as staphylococcal LTA in stimulating Toll-like receptor 2. Infect. Immun. 71:5541-5548.
15. Knapp, S., C. W. Wieland, C. van't Veer, O. Takeuchi, S. Akira, S. Florquin, and T. van der Poll. 2004. Toll-like receptor 2 plays a role in the early inflammatory response to murine pneumococcal pneumonia but does not contribute to antibacterial defense. J. Immunol. 172:3132-3138.
16. Koedel, U., B. Angele, T. Rupprecht, H. Wagner, A. Roggenkamp, H. W. Pfister, and C. J. Kirschning. 2003. Toll-like receptor 2 participates in mediation of immune response in experimental pneumococcal meningitis. J. Immunol. 170:438-444.
17. Kurt-Jones, E. A., L. Popova, L. Kwinn, L. M. Haynes, L. P. Jones, R. A. Tripp, E. E. Walsh, M. W. Freeman, D. T. Golenbock, L. J. Anderson, and R. W. Finberg. 2000. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol. 1:398-401.
18. Latz, E., A. Visintin, E. Lien, K. A. Fitzgerald, B. G. Monks, E. A. Kurt-Jones, D. T. Golenbock, and T. Espevik. 2002. Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction. J. Biol. Chem. 277:47834-47843.
19. Leclair, E. E. 2003. Four BPI (bactericidal/permeability- increasing protein)-like genes expressed in the mouse nasal, oral, airway and digestive epithelia. Biochem. Soc. Trans. 31:801-805.
20. Levy, O., S. Martin, E. Eichenwald, T. Ganz, E. Valore, S. F. Carroll, K. Lee, D. Goldmann, and G. M. Thorne. 1999. Impaired innate immunity in the newborn: newborn neutrophils are deficient in bactericidal/permeability- increasing protein. Pediatrics 104:1327-1333.
21. Malley, R., P. Henneke, S. C. Morse, M. J. Cieslewicz, M. Lipsitch, C. M. Thompson, E. Kurt-Jones, J. C. Paton, M. R. Wessels, and D. T. Golenbock. 2003. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc. Natl. Acad. Sci. USA 100:1966-1971.
22. Malley, R., M. Lipsitch, A. Stack, R. Saladino, G. Fleisher, S. Pelton, C. Thompson, D. E. Briles, and P. Anderson. 2001. Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by encapsulated pneumococci. Infect. Immun. 69:4870-4873.
23. Mannion, B. A., J. Weiss, and P. Elsbach. 1990. Separation of sublethal and lethal effects of the bactericidal/permeability increasing protein on Escherichia coli. J. Clin. Investig. 85:853-860.
24. Marra, M. N., C. G. Wilde, J. E. Griffith, J. L. Snable, and R. W. Scott. 1990. Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity. J. Immunol. 144:662-666.
25. Mold, C., B. Rodic-Polic, and T. W. Du Clos. 2002. Protection from Streptococcus pneumoniae infection by C-reactive protein and natural antibody requires complement but not Fc gamma receptors. J. Immunol. 168:6375-6381.
26. Nupponen, I., R. Turunen, T. Nevalainen, H. Peuravuori, M. Pohjavuori, H. Repo, and S. Andersson. 2002. Extracellular release of bactericidal/permeability-increasing protein in newborn infants. Pediatr. Res. 51:670-674.
27. Opitz, B., A. Puschel, B. Schmeck, A. C. Hocke, S. Rosseau, S. Hammerschmidt, R. R. Schumann, N. Suttorp, and S. Hippenstiel. 2004. Nucleotide-binding oligomerization domain proteins are innate immune receptors for internalized Streptococcus pneumoniae. J. Biol. Chem. 279:36426-36432.
28. Pangburn, M. K. 1989. Analysis of recognition in the alternative pathway of complement. Effect of polysaccharide size. J. Immunol. 142:2766-2770.
29. Park, J. M., V. H. Ng, S. Maeda, R. F. Rest, and M. Karin. 2004. Anthrolysin O and other gram-positive cytolysins are toll-like receptor 4 agonists. J. Exp. Med. 200:1647-1655.
30. Picard, C., A. Puel, M. Bonnet, C. L. Ku, J. Bustamante, K. Yang, C. Soudais, S. Dupuis, J. Feinberg, C. Fieschi, C. Elbim, R. Hitchcock, D. Lammas, G. Davies, A. Al-Ghonaium, H. Al-Rayes, S. Al-Jumaah, S. Al-Hajjar, I. Z. Al-Mohsen, H. H. Frayha, R. Rucker, T. R. Hawn, A. Aderem, H. Tufenkeji, S. Haraguchi, N. K. Day, R. A. Good, M. A. Gougerot-Pocidalo, A. Ozinsky, and J. L. Casanova. 2003. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299:2076-2079.
31. Picard, C., A. Puel, J. Bustamante, C. L. Ku, and J. L. Casanova. 2003. Primary immunodeficiencies associated with pneumococcal disease. Curr. Opin. Allergy Clin. Immunol. 3:451-459.
32. Poltorak, A., X. He, I. Smirnova, M.-Y. Liu, C. Van Huffel, X. Du, D. Birdwell, E. Alejos, M. Silva, C. Galanos, M. Freudenberg, P. Ricciardi-Castagnoli, B. Layton, and B. Beutler. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4. Gene Sci. 282:2085-2088.
33. Priebe, G. P., M. M. Brinig, K. Hatano, M. Grout, F. T. Coleman, G. B. Pier, and J. B. Goldberg. 2002. Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine. Infect. Immun. 70:1507-1517.
34. Priebe, G. P., C. R. Dean, T. Zaidi, G. J. Meluleni, F. T. Coleman, Y. S. Coutinho, M. J. Noto, T. A. Urban, G. B. Pier, and J. B. Goldberg. 2004. The galU gene of Pseudomonas aeruginosa is required for corneal infection and efficient systemic spread following pneumonia but not for infection confined to the lung. Infect. Immun. 72:4224-4232.
35. Roy, S., K. Knox, S. Segal, D. Griffiths, C. E. Moore, K. I. Welsh, A. Smarason, N. P. Day, W. L. McPheat, D. W. Crook, and A. V. Hill. 2002. MBL genotype and risk of invasive pneumococcal disease: a case-control study. Lancet 359:1569-1573.
36. Sahu, A., T. R. Kozel, and M. K. Pangburn. 1994. Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation. Biochem. J. 302:429-436.
37. Schroder, N. W., S. Morath, C. Alexander, L. Hamann, T. Hartung, U. Zahringer, U. B. Gobel, J. R. Weber, and R. R. Schumann. 2003. Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide- binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J. Biol. Chem. 278:15587-15594.
38. Schwandner, R., R. Dziarski, H. Wesche, M. Rothe, and C. J. Kirschning. 1999. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J. Biol. Chem. 274:17406-17409.
39. Srivastava, A., P. Henneke, A. Visintin, S. C. Morse, V. Martin, C. Watkins, J. C. Paton, M. R. Wessels, D. T. Golenbock, and R. Malley. 2005. The apoptotic response to pneumolysin is Toll-like receptor 4 dependent and protects against pneumococcal disease. Infect. Immun. 73:6479-6487.
40. Tweten, R. K. 2005. Cholesterol-dependent cytolysins, a family of versatile pore-forming toxins. Infect. Immun. 73:6199-6209.
41. Visintin, A., E. Latz, B. G. Monks, T. Espevik, and D. T. Golenbock. 2003. Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Toll-like receptor-4 aggregation and signal transduction. J. Biol. Chem. 278: 48313-48320.
42. Wajant, H., K. Pfizenmaier, and P. Scheurich. 2003. Tumor necrosis factor signaling. Cell Death Differ. 10:45-65.
43. Weber, J. R., D. Freyer, C. Alexander, N. W. Schroder, A. Reiss, C. Kuster, D. Pfeil, E. I. Tuomanen, and R. R. Schumann. 2003. Recognition of pneumococcal peptidoglycan: an expanded, pivotal role for LPS binding protein. Immunity 19:269-279.
44. Weiss, J., P. Elsbach, I. Olsson, and H. Odeberg. 1978. Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes. J. Biol. Chem. 253: 2664-2672.
45. Weiss, J., M. Hutzler, and L. Kao. 1986. Environmental modulation of lipopolysaccharide chain length alters the sensitivity of Escherichia coli to the neutrophil bactericidal/permeability-increasing protein. Infect. Immun. 51: 594-599.
46. Yoshimura, A., E. Lien, R. R. Ingalls, E. Tuomanen, R. Dziarski, and D. Golenbock. 1999. Cutting edge: recognition of gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J. Immunol. 163:1-5.
47. Zweigner, J., R. R. Schumann, and J. R. Weber. 2006. The role of lipopolysaccharide-binding protein in modulating the innate immune response. Microbes Infect. 8:946-952.